Last updated May 16, 2026
Audience guide · demographic
GLP-1 for Women in 2026
PCOS treatment, fertility considerations, hormonal cycle interactions
Verified by James Cole, MD, FACOGHow we review
Women have GLP-1 considerations that men do not: PCOS-specific evidence base, fertility planning intersections, pregnancy contraindications, and hormonal contraceptive absorption changes during slowed gastric emptying.
Who this guide is for
- Profile
- US adult women, ~170M. ~42% have obesity. ~10% have PCOS — often underdiagnosed.
- Common goals
- Weight management, PCOS symptom control, fertility preparation, post-partum recovery, perimenopausal weight gain.
- Constraints
- Pregnancy contraindication requires 2-month washout before conception. Oral contraceptive absorption affected during titration. PCOS not on most insurance approval criteria.
- Coverage reality
- Most commercial plans use BMI/comorbidity criteria identical to men. PCOS-specific approval is uncommon — must qualify under weight-loss/diabetes pathways.
Ranked for Women
Fit scores reflect this audience’s constraints — not raw clinical efficacy. A drug can be 9/10 overall yet 4/10 for a specific audience because of coverage or cost.
- 1Mounjaro9.0/10 fit
Tirzepatide for type 2 diabetes
Strong PCOS data emerging — tirzepatide improves insulin sensitivity + reduces androgens. Off-label for PCOS but most-studied option.
- 2Ozempic8.8/10 fit
Semaglutide approved for type 2 diabetes
Best-studied GLP-1 for PCOS metabolic improvements. T2D indication often easiest path to coverage for women with PCOS + insulin resistance.
Heads up: Stop 2 months before planned conception.
- 3Wegovy8.0/10 fit
FDA-approved semaglutide for chronic weight management
FDA-approved for chronic weight management. Standard weight-loss pathway for women without diabetes diagnosis.
Heads up: Pregnancy category X — contraception required during treatment.
- 4Zepbound8.0/10 fit
FDA-approved tirzepatide for weight loss
Highest weight loss of any approved option. Useful for severe obesity in women planning fertility treatment.
Heads up: Same pregnancy contraindication — discontinue 2 months pre-conception.
- 5Hims & Hers Weight Loss6.5/10 fit
Compounded semaglutide via telehealth
Cash-pay path when PCOS doesn't qualify for insurance coverage. Lower price makes preconception use more feasible.
Heads up: Compounded versions lack pregnancy safety data even more than brand-name.
Key considerations
- Oral contraceptive absorption
GLP-1-induced gastric slowing reduces oral contraceptive absorption during titration. Use backup contraception (condoms, IUD) for first 4 weeks and after every dose increase.
- Pregnancy washout required
All GLP-1s are pregnancy category X (animal models show fetal harm). Discontinue at least 2 months before attempting conception. Some clinicians recommend 3 months for tirzepatide.
- PCOS off-label opportunity
GLP-1s improve PCOS symptoms (insulin sensitivity, androgens, menstrual regularity, fertility outcomes). Insurance rarely approves on PCOS alone — qualify under weight or diabetes pathway.
Frequently asked questions
Can I use Wegovy if I have PCOS?
Yes, off-label. PCOS is associated with insulin resistance which GLP-1s directly address. You'll qualify for insurance via BMI/weight criteria, not the PCOS diagnosis itself — most insurers don't list PCOS in approval criteria.
When should I stop GLP-1 before pregnancy?
At least 2 months before attempting conception. Some clinicians recommend 3 months for tirzepatide due to longer half-life. Confirm with your OB-GYN — they may have additional preconception requirements.
Does GLP-1 interact with birth control?
Yes — slowed gastric emptying can reduce oral contraceptive absorption during titration and after dose increases. Use backup contraception for 4 weeks. IUDs and implants are not affected.
Audience guides synthesize coverage data, clinical recommendations, and demographic-specific constraints. Always verify your specific situation with a licensed prescriber.
Last verified: May 16, 2026